Real-Time Surveillance of Antibiotic Resistance
summary
Phase three, double blind trial enrolls 1671 women across 142 sites in four countries and directly compares oral agents with real‑world clinical outcomes. Key claims: 62.6% vs 26.6% success in cofoxy‑nonsusceptible pathogens and ~80% cure in extensively drug‑resistant infections, with overall noninferiority (65.6% vs 67.9%). Resistance findings include ~27–32% baseline resistance to common drugs and 41% acquired post‑treatment. Safety: mild diarrhea (12.4% vs 2.5%), discontinuations <3%.
AI-written summary · about
chapters (8)
- 0:00Introduction and Study Overview
- 0:41Study Design and Enrollment
- 1:34Key Findings on Antibiotic Resistance
- 2:18Efficacy of Sulopenem
- 3:14Antibiotic Resistance Analysis
- 5:34Safety and Tolerability Profile
- 6:29Therapeutic Potential and Future Directions
- 7:47Conclusion and Key Takeaways
related talks
28mClinical Data Management and Clinical Data Science A Practical Approach
19mSecure Distributed Healthcare Systems with 99.97% Availability
13mData Analytics for Security in Pharmaceutical Launches
45mFHIR Resources for Clinical Research
13mRural Health Analytics with Oracle Health
44mTrial Site to Sponsor Lab data exchange with HL7 FHIR
26mClojure vs Sepsis: path to real time enterprise data science
31mBayesian Risk Analysis For Large Multi-Modal Data